6 March 2017 - Interesting insights from the pCODR Initial Economic Guidance Report for alectinib hydrochloide (Alecensaro).

Roche submitted a partitioned survival model with three mutually exclusive health states including progression-free survival or pre- progression state, progressed disease and death.  The time horizon for the evaluation has been redacted.

The Initial Economic Guidance Report states that "Non-disclosable information was used in this pCODR Guidance Report and the manufacturer requested this information not be disclosed pursuant to the pCODR Disclosure of Information Guidelines. This information will remain redacted until March 1, 2018 or until notification by manufacturer that it can be publicly disclosed, whichever is earlier."

Alectinib hydrochloride is yet to be considered for reimbursement/subsidy by other HTA agencies.

Read pCODR Initial Economic Guidance Report for alectinib hydrochloride